Movement Alert｜Pegbio Biopharmaceuticals-B Falls 8.23% in Regular Trading, Litigation Risk and Sector Weakness Intensify Selling Pressure

Market Focus06-16

On June 16, Pegbio Biopharmaceuticals-B declined 8.23% in regular trading, trading at HK$6.48/share, with turnover of HK$35.48 million. The stock hit a fresh 52-week low amid persistent market pessimism.

The decline was driven by a combination of litigation risk overhang and broad-based weakness across the biotech sector. Since its listing, the stock has retreated significantly from its highs, with a cumulative decline exceeding 85% over the past three months, reflecting sustained erosion in investor confidence.

At the sector level, the biotechnology space traded broadly lower, amplifying selling pressure through sector linkage effects. Among peers, AKESO fell 6.1%, 3SBIO dropped 5.03%, and Innovent Bio slipped 1.81%, while BeiGene edged up 0.13% and SKB Bio gained 0.72%.

Pegbio Biopharmaceuticals is a China-based company focused on developing innovative therapies for chronic diseases. Its lead product PB-119 is a near-commercialization-stage long-acting GLP-1 receptor agonist targeting type 2 diabetes, obesity, and other metabolic diseases.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1183413158?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-16 11:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1183413158","market":"us","top_or_hot":-1,"title":"Movement Alert｜Pegbio Biopharmaceuticals-B Falls 8.23% in Regular Trading, Litigation Risk and Sector Weakness Intensify Selling Pressure","media":"Market Focus","content":"<p><p>On June 16, Pegbio Biopharmaceuticals-B declined 8.23% in regular trading, trading at HK$6.48/share, with turnover of HK$35.48 million. The stock hit a fresh 52-week low amid persistent market pessimism.</p><p>The decline was driven by a combination of litigation risk overhang and broad-based weakness across the biotech sector. Since its listing, the stock has retreated significantly from its highs, with a cumulative decline exceeding 85% over the past three months, reflecting sustained erosion in investor confidence.</p><p>At the sector level, the biotechnology space traded broadly lower, amplifying selling pressure through sector linkage effects. Among peers, AKESO fell 6.1%, 3SBIO dropped 5.03%, and Innovent Bio slipped 1.81%, while BeiGene edged up 0.13% and SKB Bio gained 0.72%.</p><p>Pegbio Biopharmaceuticals is a China-based company focused on developing innovative therapies for chronic diseases. Its lead product PB-119 is a near-commercialization-stage long-acting GLP-1 receptor agonist targeting type 2 diabetes, obesity, and other metabolic diseases.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Pegbio Biopharmaceuticals-B Falls 8.23% in Regular Trading, Litigation Risk and Sector Weakness Intensify Selling Pressure</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Pegbio Biopharmaceuticals-B Falls 8.23% in Regular Trading, Litigation Risk and Sector Weakness Intensify Selling Pressure\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-16 11:47</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 16, Pegbio Biopharmaceuticals-B declined 8.23% in regular trading, trading at HK$6.48/share, with turnover of HK$35.48 million. The stock hit a fresh 52-week low amid persistent market pessimism.</p><p>The decline was driven by a combination of litigation risk overhang and broad-based weakness across the biotech sector. Since its listing, the stock has retreated significantly from its highs, with a cumulative decline exceeding 85% over the past three months, reflecting sustained erosion in investor confidence.</p><p>At the sector level, the biotechnology space traded broadly lower, amplifying selling pressure through sector linkage effects. Among peers, AKESO fell 6.1%, 3SBIO dropped 5.03%, and Innovent Bio slipped 1.81%, while BeiGene edged up 0.13% and SKB Bio gained 0.72%.</p><p>Pegbio Biopharmaceuticals is a China-based company focused on developing innovative therapies for chronic diseases. Its lead product PB-119 is a near-commercialization-stage long-acting GLP-1 receptor agonist targeting type 2 diabetes, obesity, and other metabolic diseases.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02565","symbol_name":"派格生物医药-B","start_time":0,"source_url":"","article_id":"1183413158","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1183413158","pubTimestamp":1781581627,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 16, Pegbio Biopharmaceuticals-B declined 8.23% in regular trading, trading at HK$6.48/share, with turnover of HK$35.48 million. The stock hit a fresh 52-week low amid persistent market...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02565":"派格生物医药-B"},"translate_title":"动静提示|派格生物制药-B常规交易跌8.23%诉讼风险及板块疲弱加剧抛压","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02565":1},"content_text":"On June 16, Pegbio Biopharmaceuticals-B declined 8.23% in regular trading, trading at HK$6.48/share, with turnover of HK$35.48 million. The stock hit a fresh 52-week low amid persistent market pessimism.The decline was driven by a combination of litigation risk overhang and broad-based weakness across the biotech sector. Since its listing, the stock has retreated significantly from its highs, with a cumulative decline exceeding 85% over the past three months, reflecting sustained erosion in investor confidence.At the sector level, the biotechnology space traded broadly lower, amplifying selling pressure through sector linkage effects. Among peers, AKESO fell 6.1%, 3SBIO dropped 5.03%, and Innovent Bio slipped 1.81%, while BeiGene edged up 0.13% and SKB Bio gained 0.72%.Pegbio Biopharmaceuticals is a China-based company focused on developing innovative therapies for chronic diseases. Its lead product PB-119 is a near-commercialization-stage long-acting GLP-1 receptor agonist targeting type 2 diabetes, obesity, and other metabolic diseases.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1183413158","isCrawlerRequest":true}